Product Development and Clinical Trials - Aspire plans to submit a 505(b)(2) NDA for its high-dose sublingual aspirin product by late 2026, following positive clinical trial results demonstrating faster bioavailability compared to standard oral aspirin [26]. - The successful clinical trial completed in July 2025 involved six healthy adult volunteers and showed that Aspire's sublingual delivery technology results in much faster aspirin bioavailability in the blood [26]. - Aspire's clinical trials for its aspirin product are designed to demonstrate a shorter time to clinically meaningful pharmacodynamic effect compared to standard oral aspirin, with the next trial expected to start in summer 2026 [36]. - Aspire has completed clinical trials for high-dose sublingual aspirin and plans to file an NDA (investigational new drug application) soon [204]. - Clinical development for Aspire's product candidates is lengthy and expensive, with uncertain outcomes that may delay or prevent regulatory approval [206]. - Delays in clinical trials can arise from various factors, including patient enrollment challenges and regulatory compliance issues [207]. - Aspire relies on third parties for conducting clinical trials, which may affect the timelines and costs associated with product development [219]. Intellectual Property and Patents - The company has developed a working formulation for sublingually administered melatonin and filed for patent protection, exploring licensing possibilities for this product [37]. - Aspire has also developed formulations for sublingually administered vitamins D, E, and K, and filed for patent protection under the Omnibus Patent [38]. - The company has filed patent applications for sublingual aspirin products, with a focus on improving delivery mechanisms to enhance patient outcomes [60]. - The company has a patent application for lower dose aspirin (63/456,290) filed on March 3, 2023, which is currently pending [54]. - The company intends to file a PCT application on October 1, 2025, claiming priority to U.S. Application No. 63/702,381, with a nominal expiration of October 1, 2045 [48]. - Aspire's new patent-pending formulation for its aspirin product is designed to facilitate rapid sublingual absorption, bypassing gastrointestinal issues associated with traditional aspirin [31]. - The company has filed multiple patent applications for its product candidates, indicating a focus on protecting its intellectual property as it moves towards commercialization [202]. Manufacturing and Supply Chain - Aspire has entered into a manufacturing agreement with Glatt for the production of its high-dose sublingual aspirin, with additional agreements in place for fill-and-finish processes and future clinical trials [25]. - The company has successfully completed cGMP manufacturing of its high-dose aspirin product for clinical trials, receiving positive feedback from the FDA regarding its Pre-IND meeting request [60]. - Aspire is subject to manufacturing and supply chain risks that could increase costs and limit product supply [159]. - The company relies on suppliers for components and services, and any failure in supply could adversely impact operations [172]. - Aspire's reliance on a limited number of suppliers poses risks of business interruptions and potential delays in product manufacturing [187]. Financial Position and Funding - Aspire has incurred net losses since inception and anticipates continuing to incur substantial losses in the foreseeable future [157]. - The Company requires substantial additional financing to achieve its goals, and failure to obtain necessary capital could delay or terminate product development [157]. - The company has issued two 20% original issue discount senior secured convertible debentures totaling $3,750,000, with a conversion price set at 92.5% of the lowest daily VWAP [72]. - Aspire Biopharma, Inc. entered into a Securities Purchase Agreement on August 19, 2025, selling convertible notes worth $9,687,500 for a subscription price of $7,750,000 [80]. - The company faced a compliance deficiency with Nasdaq regarding a minimum Market Value of Listed Securities of $50 million, with a 180-day period to rectify the issue [86]. - The company also received a Bid Price Notice for failing to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq [87]. - Aspire has retained experienced consultants to develop a plan for FDA approval of the sublingual aspirin delivery mechanism [117]. Market and Competition - The company faces competition from larger pharmaceutical and biotechnology companies with greater resources and experience in product development and commercialization [43]. - The company’s ability to compete may be affected by the pricing of its products, which are expected to be at a premium over generic alternatives [45]. - Aspire's business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin, which requires significant clinical testing [157]. - The ongoing military actions in Ukraine and the Israel-Hamas conflict may adversely affect Aspire's financial position and operations due to increased market volatility and financing challenges [184]. - Aspire's technology platforms are based on novel technologies, and the regulatory approval pathway for its product candidates is unproven, which may hinder market acceptance [188]. Corporate Governance and Compliance - Aspire Biopharma, Inc. stockholders received shares of New Aspire Common Stock valued at $350 million, adjusted for cash and indebtedness at closing [67]. - The Reverse Recapitalization was completed on February 17, 2025, with PowerUp Acquisition Corp. changing its name to Aspire Biopharma Holdings, Inc. [71]. - The Reverse Recapitalization was treated as a capital transaction, with Aspire Biopharma, Inc. recognized as the accounting acquirer [74]. - The Company regained compliance with the Bid Price Rule on February 3, 2026, and met the $2,500,000 stockholders' equity rule by February 18, 2026 [89]. - The Company has incurred and will continue to incur costs to comply with a wide range of federal, state, and local regulations, which are expected to increase [183]. - Aspire is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements [149]. Product Portfolio and Future Plans - The company has initiated the marketing of its caffeine product, "Buzz Bomb," with 2,000,000 units manufactured and sales beginning on January 15, 2026 [40]. - Aspire is working on a sublingual erectile dysfunction (ED) medication, with an expected FDA approval timeline of at least 2-3 years [200]. - Aspire has developed a single serving sublingual pre-workout supplement and a "coffee or soda replacement" using patent-pending technology, with initial sales beginning in Q3 2025 [201]. - Aspire's scientists are working on formulations for various drugs, including anti-nausea products and anti-psychotic products, with several patents filed for these formulations [202]. - Aspire's high-dose sublingual aspirin product candidates are in development to treat heart attacks and strokes, with preliminary scientific evidence supporting their feasibility [189].
Powerup Acquisition Corp.(PWUPU) - 2025 Q4 - Annual Report